We prospectively studied the in vivo dialytic clearance of iron after deferoxamine (DFO) administration in four stable iron-overloaded chronic hemodialysis patients by quantifying iron concentration in blood entering and leaving the dialyzer and in dialysate after infusions of DFO. No significant arteriovenous iron differences were demonstrated. The mean ratio of venous to arterial iron approached identity at 1.005. All dialysate concentrates used contained large amounts of iron (300–610 μg/dl). No changes in efferent versus afferent dialysate iron concentration could be demonstrated. We conclude (a) iron removal during dialysis with DFO was not demonstrated; (b) the dialysate concentrate tested contained large amounts of iron; (c) in view of potentially significant toxicity, and lack of demonstrable therapeutic benefit, caution in prescribing DFO chelation therapy for iron overload is recommended.
BujaI.M., RobertsW.C.Iron in the heart. Etiology and clinical significance.Am J Med1971; 51: 209–21.
6.
KrumlovskyF.A.Cardiac function in the chronic dialysis patient.Int J Artif Organs1979; 2: 175–8.
7.
BregmanH., WinchesterJ.F., KnepshieldJ.H., GelfandM.C., ManzH.J., SchreinerG.E.Iron overload associated myopathy in patients on maintenance hemodialysis: a histocompatibility-linked disorder.Lancet1980; 2: 882–5.
8.
FoxI.Arthropathy with iron storage disease. In: KellyW., ed. Rheumatology.Philadelpia: W.B. Saunders, 1984; 1538–44.
9.
StivelmanJ., LazarusM., HakimR.Role of transfusion iron overload in metabolic bone disease in maintenance dialysis patients.Am Soc Neph Abstracts1984; 17: 29A.
10.
CzaczkesJ.W., KeynanA., BenbassatJ., AviramA.A possible way of preventing haemochromatosis in patients undergoing intermittent hemodialysis.Proc Eur Dial Transpl Assn1967; 4: 267–8.
11.
BakerL.R.I., BarnettM.D., BrozovicB.Hemosiderosis in a patient on regular hemodialysis: treatment by deferoxamine.Clin Nephrol1976; 6: 326–8.
12.
CeriatiF., PomponiM., CavicchioniC., MarinoI.R., CarelliG., CremonaG.Continuous intravenous (CIV) infusion of deferoxamine (DF) in a hemodialyzed patient with transfusion siderosis.Int J Artif Organs1981; 4: 109.
13.
CivalleriD., GoglioloG., Griffanti-BartoliF., BonalumiU., PannacciulliJ.Compartmentalization of 59 deferoxamine during hemodialysis in dogs.Boll Soc It Biolo Sper1976; 52: 455–9.
14.
LavenderS., BellJ.A.Iron intoxication in an adult.British Med J1970; 2: 406.
15.
FalkR.J., MatternW.D., LamannaR.W., ParkerN.C., CrossR.E.Iron removal during CAPD. Abstracts, Am Soc Neph 14th Annual meeting 1981; 39A.
16.
McCarthyJ.T., LibertinC.R., MitchellJ.C., FairbanksV.F.Hemosiderosis in a dialysis patient treatment with hemofiltration and deferoxamine chelation therapy.Mayo Clin Proc1982; 57: 439–41.
StanbaughG., GillitD., HolmesA.Indications for and results of long-term iron chelation in dialysis hemosiderosis.Am Soc Neph Abstracts1984; 17: 75A.
19.
StivelmanJ., HakimR., SchulmanG., FosburgM., LazarusJ.M.Iron and aluminum chelation kinetics during extended deferoxamine therapy in iron loaded hemodialysis patients. Abstracts, 18th Annual Meeting, Am Soc Neph 1985; 77A.
20.
HakimR.M., SchulmanG., LazarusJ.M.Hemoperfusion in the treatment of aluminum and iron induced bone disease. Abstracts, 18th Annual Meeting, Am Soc Neph 1985; 65A.
21.
FosburgM., HakimR.M., SchulmanG.Pharmokinetics of desferrioxamine during treatment of transfusional iron overload in chronic hemodialysis patients.Am Soc Neph, 16th Annual Meeting 1983; 46A.
22.
CiancioniC., PoignetJ.L., MaurasY.Plasma aluminum and iron kinetics in hemodialyzed patients after IV infusion of desferrioxamine.Transactions Am Soc Artif Int Organs1984; 30: 479–82.
23.
RemboldC.M., KrumlovskyF.A., RoxeD.M., FitzsimonsE., del GrecoF.Treatment of hemodialysis hemosiderosis with deferoxamine.Transactions, ASAIO1982; 28: 621–5.
SwartzR.D.Deferoxamine and aluminum removal.Am J Kidney Dis1985; 5: 358–64.
42.
LipschitzD., DugardJ., SimonM.The site of action of deferoxamine.Br J Haematol1971; 20: 395–8.
43.
PropperR., NathanD.The use of deferoxamine and “the pump”. In: ZainoE., RobertsR., eds. Chelation therapy in chronic iron overload.Miami: Symposia Specialists, 1977; 17–31.
44.
MillinerD., NebekerH., OttS.Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy.Ann Int Med1984; 101: 775–80.
45.
StummvollH., GrafH., MeisingerV.Effects of deferoxamine on aluminum kinetics during hemodialysis.Miner Electrolyte Metab1984; 10: 263–5.
46.
PippardM.J., CallanderS.T., FinchC.A.Ferrioxamine excretion in iron loaded man.Blood1982; 60: 288–94.
47.
McCarthyJ.T., KurtzS.B., MussmanG.V.Deferoxamineenhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis.Am J Med1987; 82: 367–70.
